Neogen Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Neogen is expected to report Q3 EPS of $0.05 vs $0.10 year-ago (50% decline) and consensus revenue of $204.62M vs $220.98M last year (≈7.4% decline), with results due before the open on April 9. The company announced the sale of its Genomics business to Zoetis on March 2, and shares last closed at $9.56, up 1.6% on the day. Analysts' ratings and estimates are highlighted but the preview implies weaker near-term fundamentals versus the prior year.

Analysis

The divestiture has materially reshaped the company's profit mix: recurring consumables and service-driven margins now dominate free cash flow volatility, which should compress organic revenue growth but improve predictability of gross margins over 6–18 months. That shifts competitive leverage away from high-capex genomics players toward scale players in diagnostics and food-safety consumables; suppliers with long-tail reagent contracts gain pricing power while discrete project vendors face pressure.

Near-term equity action will be driven by two linked narratives — guidance cadence and deployable cash policy. If management signals share repurchases or targeted M&A with proceeds, the market will likely re-rate multiples quickly because operating earnings volatility has fallen; conversely, prolonged reinvestment into low-return adjacencies would sustain downside. Watch revision velocity in analyst models over the next 3 months as the highest-probability catalyst set.

Tail risks are idiosyncratic execution and end-market elasticity: a softer ag-food demand environment or a delay in client renewals could amplify headline revenue declines for two quarters, while integration or carve-out transition costs could depress EBITDA by 100–150 bps in the near term. A contrarian outcome is underappreciated optionality — balance-sheet flexibility enables opportunistic tuck-ins or buybacks that materially lift EPS per share within 12 months, making current positioning vulnerable to abrupt positive repricing if clarity is provided on capital allocation.

Key Decisions for Investors

• Directional hedge into earnings (NEOG): Buy 1–2 week ATM puts sized at 1–2% of portfolio the day before the print to capture an earnings miss or weak guidance; reward scenario = 30–50% put premium gain on a >15% gap down, max loss = paid premium, cut if IV falls >30% pre-print.
• Event-driven upside spread (NEOG): If management announces a buyback/special distribution, initiate a 3-month call spread (buy ~25-delta, sell ~10-delta) sized 2% portfolio within 3 trading days of announcement; target 2.5x return, max loss = net premium (~100% of premium).
• Post-earnings volatility squeeze (NEOG): Sell a 1-week straddle/iron-condor one day after earnings if IV remains elevated, size conservatively (0.5–1% portfolio) and hedge with OTM wings to cap tail risk; objective = collect IV premium, risk = limited by put/call wings.
• Capital-allocation catalyst long (NEOG vs ZTS pair): If the company commits to meaningful buybacks within 90 days, go long NEOG equity (3% portfolio) and hedge 25% of position by shorting ZTS small size (1% portfolio) to neutralize broad animal-health beta; target 35–50% upside in 6–12 months, stop-loss 20%.